SignalCorporate
NOVAVAX EXPECTS $235M-$275M IN 2026 ADJUSTED TOTAL REVENUE WHILE TARGETING $150M-$200M IN 2028 NON-GAAP R&D AND SG&A - SEEKINGALPHA
NOVAVAX EXPECTS $235M-$275M IN 2026 ADJUSTED TOTAL REVENUE WHILE TARGETING $150M-$200M IN 2028 NON-GAAP R&D AND SG&A - SEEKINGALPHA
What changed
NOVAVAX EXPECTS $235M-$275M IN 2026 ADJUSTED TOTAL REVENUE WHILE TARGETING $150M-$200M IN 2028 NON-GAAP R&D AND SG&A - SEEKINGALPHA
Why it matters
NOVAVAX EXPECTS $235M-$275M IN 2026 ADJUSTED TOTAL REVENUE WHILE TARGETING $150M-$200M IN 2028 NON-GAAP R&D AND SG&A - SEEKINGALPHA — impact context not separately stored; see What changed.